Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised £2.2 million in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, a number of returning angels and new investors and the US-based R42 Group.
This round brings the firm’s total amount of grant and equity funding to over £10 million.
A spinout of Oxford University, ODD has been at the forefront of computer-aided drug design with its dual-track AI proprietary platform for drug discovery.
This growth capital will enable ODD to further its drug research and discovery starting with a proof-of-concept study to validate its pioneering, innovative approach against cancer.
